Tkac Jan, Gajdosova Veronika, Hroncekova Stefania, Bertok Tomas, Hires Michal, Jane Eduard, Lorencova Lenka, Kasak Peter
Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 84538 Bratislava, Slovakia.
Glycanostics Ltd, Dubravska cesta 9, 84538 Bratislava, Slovakia.
Interface Focus. 2019 Apr 6;9(2):20180077. doi: 10.1098/rsfs.2018.0077. Epub 2019 Feb 15.
The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).
本综述的第一部分详细阐述了将前列腺特异性抗原（PSA）血清学水平用于前列腺癌（PCa）诊断背后的争议。PCa诊断需要新型生物标志物，其性能要优于传统的PSA检测。该综述提供了一份详细而全面的总结，即PSA糖蛋白谱分析能够有效解决这一问题，从而大幅减少不必要的活检次数。此外，PSA糖蛋白谱分析可作为PCa的预后生物标志物，以识别具有侵袭性PCa形式的PCa患者，避免进行显著改变生活（导致尿失禁或阳痿）的不必要的进一步治疗。
